Investigation of the effect of eribulin mesilate on epithelial-mesenchymal transition in tumors of patients with metastatic breast cancer
- Conditions
- metastatic breast cancer
- Registration Number
- JPRN-UMIN000023300
- Lead Sponsor
- Fujita Health University
- Brief Summary
Erbulin could suppress EMT in some breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 22
Not provided
1)Patients with infection or patients with fever and suspected infection 2)Patient with watery diarrhea, bowel paralysis or ileus 3)Patients with fresh bleeding from gastrointestinal tract 4)History of severe drug allergy 5)Patients with severe renal dysfunction or liver dysfunction 6)Patients with interstitial pneumonia or pulmonary fibrosis revealed on chest X-rays 7)Patients with massive pleural effusion or ascites that need to be drained 8)Patients with poorly controlled hypertension or diabetes 9)Patients administrated continuously steroids for long term 10)Pregnant 11)Other active malignancies excluding carcinoma in situ cured by local treatment 12)History of severe mental disorder or central nervous system disorder 13)Patients who are judged to be inappropriate as an object for this treatment by physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change from baseline to day 15+-4 in expression of EMT related markers and vitamin D receptor in tumor tissue
- Secondary Outcome Measures
Name Time Method